ReviewFrontiers in pharmacology2022
Influence of the gut microbiota on endometriosis: Potential role of chenodeoxycholic acid and its derivatives.
Review in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 19 citations in OpenAlex.
- Microbiota-metabolite axis in endometriosis: Pathogenic mechanisms and clinical implications.Journal of biomedical research · 2026Article
- Integrated Serum Pharmacochemistry, Metabolomics, and Network Pharmacology to Reveal the Material Basis and Mechanism of Juan-tong-yin in the Treatment of Endometriosis.Applied biochemistry and biotechnology · 2026Article
- Perfluorooctane sulfonic acid impairs spermatogenesis via the liver-gut microbiota-testis axis: a central role of chenodeoxycholic acid metabolism.Journal of advanced research · 2026Article
- Nutrition and Endometriosis: Current Evidence on Dietary Risk Factors and Clinical Impact - A Narrative Review.Journal of inflammation research · 2026Review
- Follicular Fluid Amino Acid Alterations in Endometriosis: Evidence for Oxidative Stress and Metabolic Dysregulation.Biomedicines · 2025Article
- Untargeted metabolomics as a tool to assess the impact of dietary approaches on pig gut health: a review.Journal of animal science and biotechnology · 2025Review
- Plasma metabolites associated with endometriosis in adolescents and young adults.Human reproduction (Oxford, England) · 2025Article
- Leveraging the role of the microbiome in endometriosis: novel non-invasive and therapeutic approaches.Frontiers in immunology · 2025Review
- Broadening horizons: microbiota as a novel biomarker and potential treatment for endometriosis.Frontiers in microbiology · 2025Review
- The potential role of gut microbiota in the occurrence and development of endometriosis.Frontiers in cellular and infection microbiology · 2024Article
- The gut microbiota: emerging biomarkers and potential treatments for infertility-related diseases.Frontiers in cellular and infection microbiology · 2024Review
- Effects of the gut microbiota and its metabolite short-chain fatty acids on endometriosis.Frontiers in cellular and infection microbiology · 2024Review
- Gut Microbiota Disorder Contributes to the Production of IL-17A That Exerts Chemotaxis via Binding to IL-17RA in Endometriosis.Journal of inflammation research · 2024Article
- Association between gut microbiota and endometriosis: a two-sample Mendelian randomization study.Frontiers in microbiology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The gut microbiota (GM) has received extensive attention in recent years, and its key role in the establishment and maintenance of health and in the development of diseases has been confirmed. A strong correlation between the GM and the progression of endometriosis (EMS) has been observed in emerging research. Alterations in the composition and function of the GM have been described in many studies on EMS. In contrast, the GM in the environment of EMS, especially the GM metabolites, such as bile acids and short-chain fatty acids that are related to the pathogenesis of EMS, can promote disease progression. Chenodeoxycholic acid (CDCA), as one of the primary bile acids produced in the liver, is metabolized by various enzymes derived from the GM and is critically important in maintaining intestinal homeostasis and regulating lipid and carbohydrate metabolism and innate immunity. Given that the complexity of CDCA as a signalling molecule and the interaction between the GM and EMS have not been clarified, the role of the CDCA and GM in EMS should be understood from a novel perspective. However, few articles on the relationship between CDCA and EMS have been reviewed. Therefore, we review the available and possible potential links between CDCA, the GM and EMS and put forward the hypothesis that CDCA and its derivative obeticholic acid can improve the symptoms of EMS through the GM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.